Roche sues Sandoz, Teva to protect Aloxi; Pfizer goes after Apotex on Lyrica;

@FiercePharma: Novartis' desire for deals to return soon, CEO says. News | Follow @FiercePharma

> Roche has filed a lawsuit seeking to block such generic-drug companies as Novartis' Sandoz and Teva Pharmaceutical Industries from selling a low-cost version of the anti-nausea drug Aloxi. Report

> Pfizer, the world's largest drugmaker, has accused Apotex in a lawsuit of infringing two U.S. patents for the nerve-pain drug Lyrica. News

> Even with an effective vaccine, Zostavax, at the ready, the campaign against shingles has bogged down, partly because Merck has been unable to produce sufficient quantities to meet even modest demand. Article

> The European Medicines Agency will start producing monthly adverse event reports for the public as part of its plans to open up access to drug information. Item

> Shares of PDL BioPharma rose 8% after the company announced that a U.S. district court ruled in favor of the company in its ongoing patent dispute with Roche's Genentech unit. Piece

> Japan's Kyowa Hakko Kirin is to build a new manufacturing unit for oral formulations at its main production facility in Ube. Report

Biotech News

@FierceBiotech: Amgen widens cancer reach in $1B-plus Micromet deal. Story | Follow @FierceBiotech

> Pfizer, J&J's Alzheimer's drug might get boost from FDA trial rules. Item 

> Durect, Zogenix in deal for drug that could rival major J&J treatment. Story

> BioSante's female sexual dysfunction drug draws partnering interest. Report

Biotech Research News

> 'Super' stem cell keeps liver cancer going. News 

> NCI chief says no retreat from fundamental research. Story 

> Sunburn pain discovery could lead to better arthritis treatments. Article 

> Hutchinson takes lead on followup to 'Berlin Patient' HIV cure. Report 

> Metamark finds proteins that predict melanoma spread. News 

> New gonorrhea strain resistant to all available antibiotics. Story 

Manufacturing News

> EU may add environmental regs to GMPs. Item 

> Lilly: Put law enforcement on the online fakes case. Story

> Tamiflu concentration change aids dosing accuracy. Report 

> Chinese chemical inconsistency yields drug 'caveat emptor.' Story 

> Oncologist: U.S. may need drug czar to stem shortages. Article 

> Make generics look like brand drugs for safety. Item

And Finally... Scientists have proposed an intriguing new way to fight malaria: turning people into human time bombs for mosquitoes. News

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.